Stone Clinical Laboratories, a leading full-service boutique reference laboratory with facilities in Louisiana and Florida, announced today that it has entered into an agreement with the Louisiana Department of Health (LDH), to bring mass COVID-19 testing to the state.
This partnership enables Stone Clinical Laboratories to continue the fight against the novel coronavirus with the quality of its science, the strength of its clinical programs, and its industry-leading customer care and support. The entire Stone team has been working tirelessly to bring COVID-19 and anti-body testing not only to Louisiana, but several states throughout the nation. The partnership between the LDH and Stone will expand the volume and availability of testing in Louisiana.
Christopher Ridgeway, Founder and CEO of Stone Clinical Laboratories, is proud of his company’s performance during the pandemic and excited about the partnership with LDH, stating, “Stone has been dedicated to providing accessible, reliable COVID-19 testing from the beginning. The opportunity to partner with the Louisiana Department of Health enables us to continue to support the community during this time. Stone looks forward to providing industry-best laboratory testing, and we are proud to be an instrumental part of the effort to bring mass testing to the citizens of our home state of Louisiana.”
About Stone Clinical Laboratories
Founded in 2016 in New Orleans, Louisiana, Stone Clinical Laboratories (SCL) is a full-service clinical reference laboratory that specializes in preventative and molecular diagnostics testing. Stone focuses on simplifying testing, improving the efficiency of molecular diagnostics, reducing consumer and corporate cost, and increasing overall access to innovative diagnostics and the quality of patient care. SCL uses PCR-based molecular testing to detect infectious diseases and other DNA/RNA based testing, while continually enhancing its offerings in complementary diagnostic services including chemistry, microbiology, pharmacogenetic, hematology and prescription drug monitoring. Currently, SCL has two redundant laboratories, one in New Orleans, Louisiana and the other in Miramar Beach, Florida.